Prateek- Nivesh Wisdom

Yesterday was a cancelled cheque. Forget about it. Today is cash. Enjoy it! My stock analysis can be found on Insta-

[Prateek- Nivesh Wisdom @pratbrat]

This headline has become a joke

[unusual_whales @unusual_whales]

Trump says Iran deal could be reached in 'two or three days' and Strait of Hormuz will reopen 'immediately'

[Prateek- Nivesh Wisdom @pratbrat]

FY27 Estimates for CPPLUS:
Revenue = ~6,200 Cr (+47%)
EBITDA margin = 14.5%
EBITDA = ~900cr (+55.4%)
PAT = ~530 Cr (+44%)

EBITDA growth >> PAT growth means that the capex cycle is eating into earnings quality, which is actually the normal pattern when a company is in heavy investment mode.

Disc: No Buy/Sell Reco. Please do your own research.

[Prateek- Nivesh Wisdom @pratbrat]

Aditya Infotech
#CPPLUS

The STQC story is structural, real and durable — India's domestic brands now control 80%+ of the market with Chinese players effectively locked out, and Aditya Infotech at 45.4% share is the undisputed #1 with no credible domestic rival at scale.

Based on the concall, here are my FY27 earnings estimates 👇

[Prateek- Nivesh Wisdom @pratbrat]

1. +25–28% volume growth ; In line with mgmt guidance; pent-up STQC demand materialises

2. +18–22% ASP growth; Monthly price hikes pass through; IP mix continues rising to ~75%

3. margin neutral; Cost inflation offset by price hikes + localization savings. Housing plant Phase 1 (Q2 FY27) contributes ~50–80 bps. Operating leverage on fixed costs at higher revenue base

4. Lens assembly line:
Initial: 5L/month
Scalable to 10L/month
Capex: part of ₹200–300 Cr FY27 plan

5. Taiwan R&D
USD 400K invested (FY26)
Pro Series under development
Ambarella/Qualcomm AI platform in trial
Revenue impact: FY28+

[Prateek- Nivesh Wisdom @pratbrat]

@prabhakarkudva Imagine holding DLF from July 2007 till July 2026.

[Prateek- Nivesh Wisdom @pratbrat]

FY27:
Revenue: ₹5,658 Cr (+21% YoY)
EBITDA: ₹1,253 Cr (+25% · 22.2% margin)
PAT: ₹836 Cr (+11% · EPS ₹16.7)

Why revenue +21% but PAT only +11%?
FY27 is the "spend year." FY28 is when you get paid.
--------

FY28 is where the earnings follow. The key number to track is Q4 FY27 PAT annualized: ₹903 Cr — if that holds or beats, the FY28 base case of ₹1,10 Cr PAT is on track.

[Prateek- Nivesh Wisdom @pratbrat]

Himadri Speciality Chemical: FY27 is the "spend year." FY28 is when you get paid.

#HSCL

On request-
Here are my estimates for FY27 earnings👇

[Prateek- Nivesh Wisdom @pratbrat]

The key factors:
1. Carbon Black & SCB
First full year of the new 130k TPA SCB line — but utilisation depends on qualification cycles already seeded with global buyers, not new sales efforts. Chinese commodity CB dumping is the floor risk; SCB mix shift is the ceiling opportunity.

2. Coal Tar Pitch
EU REACH compliance (April 2026) hands HSCL a 15–25% export price premium that non-compliant peers simply cannot match. Structural tailwind from declining Chinese steel output tightening global tar supply — both work in HSCL's favour without any management action required.

3. Anthraquinone + Carbazole
Pure commissioning binary — comes on in Q2 or it doesn't; the import-substitution demand is already there waiting. No volume risk, no pricing risk, only execution risk on a single date.

4. Birla Tyres
Agri and OHT brand heritage is real, the dealer network is built, and tractor demand provides a floor — but the business is still buying market share at sub-scale utilisation with HSCL's balance sheet absorbing the losses. FY27 is a credibility year, not an earnings year.

5. LFP Cathode + Anode
Commissioning starts the OEM approval clock, not the revenue clock — the real FY27 event is whether IBC's Bengaluru gigafactory comes on in Q4 and becomes HSCL's first named offtake anchor. Everything else in this segment is samples, not sales.

[Prateek- Nivesh Wisdom @pratbrat]

As of early June 2026, the current margin lending balance in South Korea has reached an all-time record of approximately $25.1 billion.

Now KOSPI 200 Futures 6% down, even today!

Yeh South Korea sabko leke doobega 😀😀

[Prateek- Nivesh Wisdom @pratbrat]

@khyati_SD sure..will do.

[Prateek- Nivesh Wisdom @pratbrat]

Sterlite Technologies
#STLTECH

From the Q4 FY26 earnings concall, here is my FY27 earnings scenario (don't forget to read till the end) 👇

[Prateek- Nivesh Wisdom @pratbrat]

FY27 RISKS for STLTECH:

Of course, it all goes for a toss if:
1. Germanium supply constrained → utilisation capped at 55–60%
2. Prysmian litigation adverse outcome — USD 100 Mn liability crystallises in FY27

This may cause PAT to go into negative territory.

The germanium constraint alone — without Prysmian — leaves STL operationally marginally profitable at ₹47 Cr PAT.

Disc: No buy/sell reco. Please do your own research.

[Prateek- Nivesh Wisdom @pratbrat]

FY27 ESTIMATES for STLTECH:
Revenue = ₹6,800 Cr (+43.3% YoY)
EBITDA margins = 16.0% margin
EBITDA = ₹1,088 Cr (+73.2%)
PAT = ₹214 Cr (+282%)

[Prateek- Nivesh Wisdom @pratbrat]

In this bear market at the #nifty index level, a bottoms-up stock picker will find more than the required genuinely good opportunities.

[Prateek- Nivesh Wisdom @pratbrat]

@udaykotak Please don't blame the IPL Sir !!!
In a country where govt cares more about winning an election (through freebies) than the betterment of the country, our dreams will remain a dream.

[Prateek- Nivesh Wisdom @pratbrat]

Vishwa Guru !!

[Subhash Chandra Garg @Subhashgarg1960]

India’s economy under Modi led BJP has gone worse from ‘fragile five’ to ‘vulnerable one’. No economy today is as vulnerable to growth, inflation, investment, exports, fiscal deficit shocks as India. Unhappy days ahead. Modi deforms have cost India badly. https://t.co/3sB1OwQLDu

[Prateek- Nivesh Wisdom @pratbrat]

Mumbai ki pehli baarish cannot save the Indian stock market from the newly proposed US 12.5% tariffs + plus high crude + ...

2021-2030 was supposed to be India's decade. Vishwa Guru?

Now turning out to be one of the worst decades. India has fallen behind the Energy + Compute race.

Only two things that matter!

[Prateek- Nivesh Wisdom @pratbrat]

@JooFerreir73578 i think so

[Prateek- Nivesh Wisdom @pratbrat]

Supriya Lifescience
#SUPRIYA

Based on Q4, FY26 management guidance of company achieving ₹1,000 cr topline conservatively by FY27, let us try to construct full FY27 earnings projection 👇